GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Rainmed Medical Ltd (HKSE:02297) » Definitions » Common Stock

Rainmed Medical (HKSE:02297) Common Stock : HK$3,000.25 Mil (As of Jun. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Rainmed Medical Common Stock?

Rainmed Medical's quarterly common stock declined from Jun. 2023 (HK$3,048.29 Mil) to Dec. 2023 (HK$3,048.28 Mil) and declined from Dec. 2023 (HK$3,048.28 Mil) to Jun. 2024 (HK$3,000.25 Mil).

Rainmed Medical's annual common stock increased from Dec. 2021 (HK$0.00 Mil) to Dec. 2022 (HK$3,112.21 Mil) but then declined from Dec. 2022 (HK$3,112.21 Mil) to Dec. 2023 (HK$3,048.28 Mil).


Rainmed Medical Common Stock Historical Data

The historical data trend for Rainmed Medical's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rainmed Medical Common Stock Chart

Rainmed Medical Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Common Stock
- - 3,112.21 3,048.28

Rainmed Medical Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Common Stock Get a 7-Day Free Trial - 3,112.21 3,048.29 3,048.28 3,000.25

Rainmed Medical Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Rainmed Medical Business Description

Traded in Other Exchanges
N/A
Address
No. 99, Jinji Lake Avenue, Building 31, Northeast District, Suzhou Industrial Park, Jiangsu Province, Suzhou, CHN, 215000
Rainmed Medical Ltd is focused on the design, development, and commercialization of coronary angiography-derived fractional flow reserve systems and coronary angiography-derived index of microcirculatory resistance systems. The company's core products, the caFFR system and the caIMR system are medical devices used to evaluate the severity of myocardial ischemia arising from coronary artery stenosis and microvascular dysfunction, which are the underlying causes of coronary artery diseases (CAD). It operates in China and Other countries.
Executives
Huo Yunfei 2101 Beneficial owner
Zhou Bin
Zhong Guo Ping An Bao Xian Ji Tuan Gu Fen You Xian Gong Si
Xi Zang Jing Jia Qi Ye Guan Li You Xian Ze Ren Gong Si
Shang Hai Jing Lin Gu Quan Tou Zi Guan Li You Xian Gong Si
Shang Hai Jing Wu Tou Zi Zhong Xin You Xian He Huo
Shang Hai Jing Mai Run Qi Ye Guan Li Zhong Xin You Xian He Huo
Gong Qing Cheng Jing Cheng Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Gong Qing Cheng Jing Lin Jing Jia Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Jing Lin Zi Ben Guan Li You Xian Gong Si
Shen Zhen Jing Lin Jing Ying Gu Quan Tou Zi Ji Jin He Huo Qi Ye You Xian He Huo
Shen Zhen Jing Hui Gu Quan Tou Zi Guan Li He Huo Qi Ye You Xian He Huo
Shang Hai Tong Xiang Hao Qian Qi Ye Guan Li He Huo Qi Ye You Xian He Huo
Xi Zang Jing Ning Qi Ye Guan Li You Xian Ze Ren Gong Si
Liu Li Rui

Rainmed Medical Headlines

No Headlines